SmartKem Drives International Growth Strategy with Appointment of Bill Freer as Chairman

(29 March 2012) - SmartKem Limited, the developer of high performance, printable organic semiconductor materials for flexible electronics, today announced the appointment of Bill Freer as company chairman. Bill holds extensive experience in the global display’s and semiconductor industries, having built up a successful track record in senior management positions for a variety of industry-leading organizations, worldwide. The past 10 years have seen Bill work with a number of venture capital backed start-up companies, utilizing his corporate experience at large multinationals to assist them in developing strategies and strengthen their positions in the market. This experience, coupled with a proven track record of building relationships with electronics manufacturers in Asia, make Bill perfectly suited to guide SmartKem’s expansion into the Asian market. 
 

Bill brings to the role a breadth of experience and knowledge in the displays and semiconductor markets, having worked with leading organisations throughout a career spanning 40 years. During his time in the industry Bill has built up and maintained a variety of companies, including managing the turnaround of an ailing LCD organisation in Hong Kong into a highly profitable business with a 35% market share. His knowledge of growing businesses in Asia, along with the networks he has built up in the region will facilitate SmartKem’s aim of supplying its materials to device manufacturers and OEM’s in the Asian market.

Over the last 10 years, Bill has utilized his widespread experience in technology development, mass manufacturing and commercial exploitation to work in partnership with a number of global start-up enterprises to enhance their business activities. During this time he has consulted and held board positions with enterprises involved in LED, OLED, FED and MEM display technologies in Europe, USA and Japan. This experience, teamed with his strong connections to the venture capital market will prove vital in supporting SmartKem’s mission of becoming the leading provider of low cost, ‘p’ type organic semiconductor materials for ultra-thin and flexible electronics.

Commenting on his appointment Bill stated: “There is a clear need for SmartKem’s state-of-the-art materials in the rapidly changing printed electronics industry. The company has developed its materials to meet market demand for low cost, low energy and lightweight electronics, while also ensuring that they have better levels of mobility than those of its high-profile competitors. SmartKem’s flexible market approach allows it to respond quickly to changing needs of the market, making the company hugely appealing to potential investors.”

“We are very pleased to welcome Bill to the team” says Steve Kelly, CEO at SmartKem. “We made the decision to appoint Bill as his second-to-non industry experience in the international displays market, combined with the networks he has built up over the years in our desired regions mean Bill will bring invaluable knowledge to the company. We are confident that Bill will fit in with SmartKem’s strategy seamlessly and help reinforce our position industry-wide, whilst his strong connections in the venture capital market will provide us with a platform for further growth and investment.”

This appointment is another step in SmartKem’s global strategy and comes following the recent appointments of representatives in Japan, Korea and Taiwan.

For more information on SmartKem and its innovative materials, please call 01745 535190, email enquiries@smartkem.com or visit www.smartkem.com

About SmartKem

SmartKem is a high tech enterprise developing an exciting new technology platform focusing on high performance/ organic semiconductor materials that can be ‘printed’ onto lightweight low cost polymer films to deliver flexible circuits. SmartKem’s main objective is to respond to the demand for low cost, low energy, lightweight, rugged electronics. The SmartKem team has proven expertise and experience in the fields of organic semiconductors, specialist ink-technology and printable transistors and was a recent winner of the inaugural Oxford Venturefest gold award for ‘British Technology Innovation of the Year’.

For further press information please contact: Celine Goodier, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, United Kingdom Tel: + 44 (0)1477 539539 Fax: +44 (0)1477 539540  E-mail: smartkem@scottpr.com

PRECOS Unveils Innovative Range of Platforms for Drug Discovery and Biomarker Oncology Studies at AACR Annual Meeting 2012

NOTTINGHAM, UK (26 March 2012) – Preclinical Oncology Services Limited (PRECOS), a leading pre-clinical research and development service provider with a specific focus on oncology, is to launch its series of unique platforms for pre-clinical oncology at the AACR Annual Meeting (Chicago, March 31^st – April 4^th 2012, booth #4306). From target validation, through in vitro and in vivo to histological services, the company’s validated platforms are used extensively in collaboration with prominent pharmaceutical and biotechnology companies to offer enhanced research productivity for specific targets.

 At the show PRECOS will highlight the following key platforms:

• PREval Platform for Target Validation – a comprehensive service using cutting-edge molecular biology tools for validating the effect of specific genes via knockdown or activation/amplification both in vitro and in vivo. PRECOS provides a customised approach for each target.

• PREpare Platform for PK and PD - a variety of in vitro, in vivo and in silica services to determine the correct closing regimen for a project. This platform provides pharmacokinetic and pharmacodynamics insights into a therapeutic agent. In order for any potential drug to show the desired effect in vivo, it is necessary to determine potency at the target and to ensure sufficient exposure is achieved.

• PREcise Platform for In Vitro and In Vivo screening - a full repertoire of over 150 cancer cell lines matched with a comprehensive range of cellular assays available to run in 2-D assays, 3-D TGA (tumour growth assays), recapitulation of 3-D models with cancer-associated fibroblasts or mesenchymal stem cells. PRECOS has extensive experience in combination studies both in vitro and in vivo, orthotopic and metastatic models as well as simple subcutaneous xenograft models.

• PREdict Platform for Target Discovery - unique primary tissue panels of patient-derived in vitro and in vivo models, characterised, validated and ready to run in studies.

“PRECOS provides an expert range of research services for pre-clinical oncology, validated through its established track record with its leading clients. Our panels are designed to help our clients address their key needs and challenges by providing cutting-edge clinically relevant models that are ready to run in both in vitro and in vivo,” said Dr Neil Rotherham, chairman of the PRECOS board. “We have an established track record in providing expert support to direct cancer drug development projects and our new platforms are applicable from concept to clinic. We will be launching our first output from the platforms which will be announced at AACR 2012, visit booth #4306 to learn more.”

PRECOS offers innovative science, expert advice and accurate, reproducible models to advance research and support compound development projects. For further information please call +44 (0)870 166 6234, e-mail enquires@precos.co.uk or visit www.precos.co.uk.

About PRECOS Ltd

PRECOS Ltd. is a flexible pre-clinical research and development service with a specific focus on oncology, with an established track record in providing expert support to direct cancer drug development projects from concept to clinic. PRECOS evaluates the innovative cancer medicines of the future in patient-relevant models to ensure that pre-clinical efficacy assessment is predictive of how the drug is likely to behave in clinical trials with cancer patients. The PRECOS team of expert scientists assist in the selection and execution of appropriate analytical systems by a staged approach of in vitro studies, in vivo model development, subsequent in vivo mechanistic and therapeutic evaluations and post-study analyses, all conveyed with added value through specialist scientific interpretation of the data. PRECOS scientists apply cutting-edge technology and ideas to individual research programmes and delivers a flexible, tailored approach to all research objectives, whether a one-off service or a complete research programme.

 PRECOS, an acronym of Pre-Clinical Oncology Services, was officially launched as a specialist business unit of the University of Nottingham (UK) in 2004. PRECOS evolved from the research expertise of the Division of Pre-clinical Oncology (formerly Academic Unit of Studies), which had successful collaborations with pharmaceutical and biotech companies in the UK, EU, US and Japan for over a decade. For further information: www.precos.co.uk

 For further press information please contact: Sarah Evans - The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom. Tel: + 44 1477 539 539 Fax: +44 1477 539 540 E-mail: precos@scottpr.com

 

StarDrop 5.2 Adds New FieldAlign Plug-in Module

Optibrium unveils the first output from its collaboration with Cresset

CAMBRIDGE, UK, 20 March 2012 – Optibrium, developer of software solutions for drug discovery, today announces a new version of its StarDrop™ platform. StarDrop 5.2 features a new plug-in module that provides users with access to Cresset’s FieldAlign™ technology, which offers a unique, 3-dimensional insight into the biological activity of their compounds. This new development is the first result of the technology exchange between Optibrium and Cresset announced earlier this year, and adds another powerful tool to StarDrop that will enable chemists to understand the 3D structure activity relationship (SAR) of their chemistry in order to optimise their compounds.

Achieving a combination of potency with appropriate ADME and safety properties is essential to the discovery of high quality drug candidates. Optibrium’s StarDrop platform helps to identify compounds with a good balance of properties by integrating in silico and experimentally measured data using a unique multi-parameter optimisation approach, chemical space visualisation and intuitive data analysis. StarDrop’s interactive designer with Glowing Molecule™ visualisation guides the exploration of compound design strategies with instant feedback on the impact of changes on a compound’s predicted properties. These core features can be extended with plug-in modules to predict key ADME properties and P450 metabolism, build and validate robust QSAR models of in-house compounds and data, and automatically generate new, relevant compound ideas. The new FieldAlign module in StarDrop adds a powerful 3D view of compound interactions that will complement StarDrop’s existing 2D QSAR models.

FieldAlign provides a unique insight into the biological activity, properties and interactions of molecules. Using fields, biologically meaningful comparisons can be made that are not limited by two-dimensional structure. FieldAlign is a powerful molecular design and 3D SAR tool that allows the molecular fields of multiple compounds to be compared in their bioactive conformations. By highlighting both similarities and differences between molecules, FieldAlign shows where and how lead molecules bind to their protein target. This enables regions of active molecules that can be replaced, to be quickly identified, to perfect the design of a new lead compound. Furthermore, given the 3D structure of an active molecule and a series of 2D compound structures, FieldAlign will generate the best 3D alignment for the compounds, scored and ranked according to their field similarities with the known active. With this information, small compound libraries can be screened to look for novel series with greater structural diversity, and the design of focused libraries can be optimised for synthesis or initial screening.

Version 5.2 also introduces new enhancements of StarDrop’s core capabilities, in particular a flexible tool for performing automatic R-group analysis. This new feature analyses a chemical series to interactively visualise the impact of variations to R-groups, linkers, atoms or fragments on compound properties to help chemists to further understand the SAR of their chemistry and identify new optimisation strategies.  StarDrop can also enumerate the full, combinatorial library to explore the properties of compounds that have not yet been synthesised and identify potential missed opportunities.

Matt Segall, CEO of Optibrium, commented “We are excited to be able to provide a great range of new features to our users, continuing to extend StarDrop’s seamlessly integrated environment that helps to guide the efficient identification of high quality compounds. We are particularly pleased that our new collaboration with Cresset has so quickly yielded an important new capability for the StarDrop platform and look forward to continuing to work with Cresset on further joint projects.”

StarDrop 5.2 will be launched at the upcoming American Chemical Society Spring Meeting and Exposition in San Diego, CA, March 25-29. Visit Optibrium’s stand (#1419) for a first sight of this exciting new release. Further information on StarDrop can also be found at www.optibrium.com or by calling +44 1223 815900.

About Optibrium Ltd

Optibrium (www.optibrium.com) is dedicated to providing software to guide decisions involving complex, uncertain data in an intuitive way. Based in Cambridge, UK, Optibrium has a global customer base ranging from top-ten pharmaceutical companies to small biotechs and academic groups. Our mission is to continue to develop new technologies that will optimise project strategy, reduce wasted molecules and experiments, shorten timelines and improve the quality of candidate compounds for our clients. Optibrium’s primary product, StarDrop, is focused on the drug discovery industry, helping guide scientists to make decisions in the design and selection of high quality drug candidates. Visit the online community at http://www.optibrium.com/community/ for further discussions on improving the productivity of drug discovery.  

For further press information please contact: Sarah Evans, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, UK Tel: + 44 1477 539539 Fax: +44 1477 539 540 E-mail: optibrium@scottpr.com.

About Optibrium Ltd

Optibrium (www.optibrium.com) is dedicated to providing software to guide decisions involving complex, uncertain data in an intuitive way. Based in Cambridge, UK, Optibrium has a global customer base ranging from top-ten pharmaceutical companies to small biotechs and academic groups. Our mission is to continue to develop new technologies that will optimise project strategy, reduce wasted molecules and experiments, shorten timelines and improve the quality of candidate compounds for our clients. Optibrium’s primary product, StarDrop, is focused on the drug discovery industry, helping guide scientists to make decisions in the design and selection of high quality drug candidates. Visit the online community at http://www.optibrium.com/community/ for further discussions on improving the productivity of drug discovery.  

For further press information please contact: Sarah Evans, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, UK Tel: + 44 1477 539539 Fax: +44 1477 539 540 E-mail: optibrium@scottpr.com.

The Scott Partnership arrival at the reception held at the residence of The British High Commissioner in Delhi.

Kath Darlington, CEO, joined the Rt. Hon. Dr Vince Cable, secretary of state for business, innovation and skills at the British event in India on Friday 16 March 2012.

Coronation Street Wedding Dress Seeks New Bride in aid of Ronald McDonald House at Alder Hey

15th March 2012: The bridal gown worn by Coronation Street’s Sian Powers, played by actress Sacha Parkinson, is to go under the hammer in aid of the Ronald McDonald House at Alder Hey Children’s Hospital.

The size 10, Forever Unique gown has been donated by Granada and is under auction by sealed bids to be opened at the charity’s annual fundraising ball on 24th March 2012.

The Ronald McDonald House is on the grounds of the world famous children’s hospital and provides accommodation, free of charge, to thousands of families of critically ill children.

“We are thrilled to receive such an unusual donation,” says house director Jan Thomas, “We are arranging the auction to allow as many brides and memorabilia collectors as possible to have the chance to own this special gown.”

The house needs to raise in the region of £500K each year to keep its doors open and it relies heavily on the many families who become friends and support its work through fundraising, donations and in kindness. The 84 room house is open 365 days a year and provides bedrooms and a place for families to rest, relax, cook, clean and be together away from the stress of the hospital ward.

Interested bidders should register their interest directly to the house via email at ronmchouse1@hotmail.com or by post marked ‘Sian’s wedding dress’ at Ronald McDonald House, Alder Road, Liverpool, L12 2AZ or call the House Director on 0151 252 5869. The auction will take place at the Crowne Plaza Liverpool on 24th March.

Attached images by Eamonn and James Clark and Cavendish Press: actresses Sacha Parkinson and Brook Vincent in their matching Forever Unique gowns.
For further information please contact: Jan Thomas, House Director
Ronald McDonald House tel 0151 252 5869 email: ronmchouse1@hotmail.com

Editors Notes: About Ronald McDonald House at Alder Hey
Ronald McDonald House at Alder Hey hospital in Liverpool is Europe’s biggest Ronald McDonald House at Europe’s biggest and busiest children’s hospital and provides a home away from home for families of critically ill children.

The house has expanded over the years to 69 bedrooms and was delighted to receive HRH the Duchess of Cambridge who formally opened an additional 15 apartments for long-stay families earlier this year, the result of the hard work of many families who together raised over £1million to support this growth.

Since 1993 the house has offered free of charge accommodation to thousands of families who stay for as long as the treatment of their child takes. Some stay just a few days, some several weeks and some up to a couple of years. Their children have a wide range of conditions – some have heart problems, others have cancer or leukaemia, some need neurosurgery. Many children are in hospital as a result of a serious accident.

The house needs to raise £500,000 each year to keep its doors open and conducts a number of fundraising events throughout the year. Further information about the house and how to fundraise are available at http://www.machousealderhey.org.uk/index.html

Synergy Health Becomes First Operational Partner at UK’s Newest Hospital

Capital Hospitals selects hospital sterile services partner for Royal London Hospital

March 1st 2012 – The new Royal London Hospital (RLH), part of Barts and the London NHS Trust and the UK’s biggest hospital, has partnered with Synergy Health for its hospital sterile services.

The now operational Synergy Health facility, housed within the new Royal London site will serve the hospital’s 23 on-site theatres; decontaminating and sterilising approximately five million surgical instruments each year. The facility will also be linked to the London Chest Hospital by lifts enabling rapid access between the two different parts of the hospital and with plans to provide services both on and off-site.

The company was selected by Capital Hospitals Limited as a key delivery partner alongside Skanska, Carilion, Siemens and Varian and is the continuation of a long relationship with the Trust where it has provided sterile services to St. Bartholomew and the London Chest hospital since May 2006.

Synergy Health is one of the first tenants in the new hospital after relocating its service from an interim facility at Wharf Road, Islington. The Islington site was built as a transitional, yet highly advanced and fully operational service that fulfilled all sterilisation requirements while the new RLH facility was being built. This was vital to ensuring sustained and consistent quality and efficiency and ensured the move posed no risk to patients. The final transition to the new site took place following the full accreditation of the unit.

The Trust will benefit from efficiency and quality enhancements enabled by Synergy Health’s state-of-the-art technology, equipment and specialist staff - many of whom were employed by Barts and the London NHS Trust from before services transferred to the Islington site in 2006. Training of new staff has taken up to 18 months and all staff at RLH undertook training for fire safety and the use of new equipment. NHS staff which transferred under TUPE included 33 technicians, five team leaders, six support staff and nine distribution staff who joined the Synergy team to bring the full unit complement to 60 The team operates a round-the-clock on-call service to support emergencies and major incidents. During the summer riots the team was able to scale up to ensure the Trust’s needs were met.

The Trust’s Medical Director Dr. Steve Ryan said: “Like all of our key delivery partners Synergy Health will play a critical role in ensuring the timely, quality and consistent delivery of its expert service. Sterile services are critical to ensuring our surgeons and other healthcare professionals can rely on having the tools of their trade available through a safe, timely and traceable service and where patient safety features top of all agendas. By being located so close to our theatres we expect the sterile services unit to be able to provide an unrivalled service to our staff and - most importantly - our patients.”

Synergy Health CEO UK and Ireland Adrian Coward adds: “We are delighted to have been chosen as a key delivery partner to provide sterile services through our best-in-class facility at this fantastic new hospital. We continually strive for mutual success based on trust, innovation and accountability and where we are focused on the needs of the hospital to deliver the utmost patient care at the best possible cost.

I am gratified to see the extreme efforts made by our staff to enable the transition to the new hospital with minimal disruption and which I know has involved many long hours! We look forward to working with the Trust to ensure that this flagship hospital continues to enjoy the reputation for which it is renowned.”

The new hospital plans to revolutionise the hospital experience for patients who will benefit from cutting edge facilities and standards of care to rival the best in Europe. The layout and facilities within the hospital have benefited from the input of clinicians to ensure they are able to provide safe and patient-focused clinical care. It will be completed by 2015.

For further press information please contact: Sarah Evans, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire. CW4 8AA United Kingdom Tel: + 44 1477 539539 Fax: +44 1477 539540 mail to: synergy@scottpr.com

Notes to editors:

About the Royal London - Update
The final stages of preparation for the new hospital at The Royal London are now underway, in anticipation of wards and departments starting to move in this month. The moves will take place over a three-month period – from 6 December until 28 February 2012 – from buildings across The Royal London and Barts.

The first services to transfer into the new building in December include A&E and supporting services. The final departments to move in will be women’s and children’s and renal in February 2012.

For further information about the Royal London Hospital please contact: Mark Mann, Head of External Communications, Communications Department, Barts and The London NHS Trust at mark.mann@bartsandthelondon.nhs.uk or 020 7480 4837.

About Synergy Health

Synergy Health is the largest provider of outsourced sterilisation services in Europe with 19 facilities across the UK and further facilities in Belgium, Netherlands and China. It safely sterilises around 60 million surgical instruments each year from NHS acute and primary Trusts and the independent sector throughout the country.

Synergy Health delivers a range of specialist outsourced services to healthcare providers. These services are aimed at supporting customers to improve the quality and efficiency of their activities, while increasing patient safety and risk to clients.

To learn more about Synergy Health’s services, please visit www.synergyhealthplc.com, contact decontamination@synergyhealthplc.com or call (44) 0 1582 501234

About Capital Hospitals Limited

The delivery of the new hospitals is the joint responsibility of Barts and The London NHS Trust and Capital Hospitals, a consortium of the project’s shareholders: Innisfree, Skanska Infrastructure Development and Dutch Infrastructure Fund, some of the biggest and most experienced names in the delivery of acute hospital developments.
The contract with Capital Hospitals started in April 2006. The consortium raised the £1 billion of finance needed to fund the project, has responsibility for the construction of the new hospitals and is providing facilities management services, both during this interim phase for the existing estate and once the new hospitals become available; a contract that runs for 42 years in total.

Microsaic Systems Exhibits the World’s Smallest MS System at Analytica 2012

(Woking, March 1st 2012) Microsaic Systems plc, the high technology company developing next generation mass spectrometry instruments, is to exhibit the Microsaic 3500 MiD at Analytica 2012, Munich, 17th – 20th April 2012, Hall A2, Booth 240. Developed in collaboration with three major pharmaceutical companies, the 3500 MiD® is the world’s first chip-based mass spectrometer is an extremely robust system which is simple and intuitive to use. 90% smaller than conventional mass spectrometers and with fewer infrastructure requirements, the revolutionary Microsaic 3500 MiD is a versatile, portable solution for bench chemists in medicinal chemistry laboratories. Able to be configured and ready to use in one hour, the drastically reduced footprint and ease of use means the 3500 MiD is the ideal mass spectrometer for the modern laboratory.

Microsaic Systems has successfully transformed mass spectrometry by integrating key miniaturised components onto patented chip technologies called ionchip®, spraychip®, and vac-chip. The core technologies are chip-scale versions of traditional mass spectrometry components which can be interchanged rapidly by the user, enabling greater adaptability and speed of use. The 3500 MiD is the only MS system on the market which does not require an external vacuum pump, and is significantly smaller than legacy systems. The ability to control the 3500 MiD remotely via a LAN connection removes the need for a monitor or keyboard next to the system, further minimizing the footprint, meaning the product is small enough to sit inside a fume hood. Previously, MS had only been used for off-line analysis but with the 3500 MiD MS analysis can be now performed on-line within the fume-hood.

The 3500 MiD is designed to integrate with existing HPLC equipment with no extra footprint and no infrastructure requirements (e.g. sound proofing, A/C). Other separation methods such as Prep LC, Flash LC and SFC can also be combined with the 3500 MiD to offer mass directed purification. The ability to monitor reactions in real time provides the chemist with vital data which can be acted upon to rapidly speed up reaction optimisation, improve safety and save valuable time.

The company’s products retain the functionality of larger conventional MS systems but are considerably smaller, lighter, consume less energy and operate at only 10% of the standard running costs. The highly innovative modular approach enables users to maintain the system without the need for expensive service contracts and time consuming call outs. Users are able to increase the use of mass spectrometry in the lab while benefiting from significant cost savings owing to fewer necessary structural components such as gas generators and air conditioning. There are also sizeable savings with the use of ‘Plug and Play’ components which enable users to maintain the system themselves, resulting in less downtime and greater flexibility within the laboratory.

“Microsaic Systems has revolutionised MS by developing the world’s first chip based mass spectrometer,” said Professor Eric Yeatman, Acting CEO of Microsaic Systems. “The 3500 MiD is compatible with a wide range of methods, flow rate and solvents. The ‘plug and play’ chips make the 3500 MiD configurable, flexible and future proof and its greatly reduced footprint means mass spectrometry is now more accessible to more laboratories than ever before.”

For more information about the Microsaic 3500 MiD system, please visit the Microsaic Systems booth at Hall A2 – Booth 240, Analytica 2012. Alternatively please call +44 1483 751 577, email media@microsaic.com or visit www.microsaic.com

About Microsaic Systems plc

Microsaic Systems plc is a high technology company developing and marketing next generation mass spectrometry (MS) instruments for the analysis of gaseous, liquid and solid samples. Microsaic has successfully miniaturised mass spectrometry by integrating the key MS components onto patented chip technologies called ionchip®, spraychip® and vac-chip. Microsaic’s MS products retain the speed and sensitivity of larger, conventional MS systems but are substantially smaller, lighter, consume less energy and have lower running costs. The Company’s first product, the Microsaic 3500 MiD®, was launched in January 2011 and is the world’s smallest MS system.

Microsaic Systems plc was established in 2001 to develop miniaturized MS instruments based on Micro-Electrical-Mechanical Systems (MEMS) originating at the highly regarded Optical and Semiconductor Devices Group at Imperial College London. Microsaic has subsequently established a large portfolio of 88 patents, of which 36 are granted. The Company has been based at headquarters in Woking, UK since September 2004 and was admitted to AIM, a market of the London Stock Exchange, in April 2011 (ticker: MSYS).

For further press information please contact: Sarah Evans, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire. CW4 8AA, United Kingdom Tel: + 44 1477 539539 Fax: +44 1477 539540 mail to: pr@scottpr.com